ClinicalTrials.gg
RecruitingNCT06166771Updated Oct 23, 2024

Safety and Effectiveness of the Alma System in Treating Primary Postpartum Hemorrhage

An interventional study of Alma system in Postpartum Hemorrhage \(PPH\), Postpartum Hemorrhage \(Primary\) and PPH, sponsored by ResQ Medical Ltd. Recruiting at 1 site in Kenya. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-23.

Sponsored by ResQ Medical Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

Postpartum Hemorrhage (PPH) is an obstetric emergency that can occur up to 24 hours after vaginal birth or cesarean section.

In most cases, the uncontrolled bleeding is due to a lack of sufficient contraction of the uterus (hypotonia) and appears immediately after birth.

The purpose of this prospective, non-randomized, feasibility pilot study is to obtain information on the safety and effectiveness of an investigational new medical device - Alma System, that is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted.

Read the detailed description

A prospective, non-randomized, feasibility pilot study that is intended to obtain information on the safety and effectiveness of the Alma System.

Study population: Women with vaginal deliveries in a hospital setting who failed first-line therapies for postpartum hemorrhage.

The main questions are:

  1. Rate of device related SAEs up to six weeks following device treatment.
  2. Rate of any observable damage to cervix, uterus or vagina during or immediately after device procedure.
  3. Rate of occurrence of uterine inversion of folding during or immediately after device procedure.

Main tasks for participants:

  • sign the informed Consent form and enrolment
  • In case of PPH, treatment with Alma
  • Participate in 2 follow-up visits After the treatment- 1st upon discharge and 2nd after 6 weeks.
02

Conditions studied

  • Postpartum Hemorrhage \(PPH\)
  • Postpartum Hemorrhage \(Primary\)
  • PPH

Browse trials for

Keywords

  • alma, pph, post partum hemorrhage
03

In context

Postpartum Hemorrhage

471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

This study's planned enrollment of 10 is below the median of 148 across 362 interventional studies indexed under Postpartum Hemorrhage.

Browse Postpartum Hemorrhage studies →

Lead sponsor

ResQ Medical Ltd is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult Female, 18 years of age or older at time of consent.
  2. Subject or her legally authorized representative is able to understand and provide consent to participate in the clinical investigation.
  3. Subjects who present with an atonic uterus for at least 10 minutes after expulsion of placement with failure to obtain contraction and/or Subjects who have lost blood post-partum > = 500 ml and according to the Investigator's judgment, require an intervention.
  4. Failed intervention of uterotonics and uterine massage/bimanual uterine massage to stop bleeding.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who do not provide to participate in the clinical investigation.
  2. Subjects who deliver at a uterus size \< 34 weeks.
  3. Subjects who have lost greater than 1000 ml of blood.
  4. Subjects who have abnormal PT, and INR
  5. Subjects who present with retained placenta, uterine lacerations, or for any other conditions outside of atonic post-partum hemorrhage.
  6. PPH that the investigator determines to require more aggressive treatment, including any of the following:

    • Hysterectomy;
    • B-lynch suture;
    • Uterine artery embolization or ligation;
    • Hypogastric ligation.
    • Known uterine anomaly.
    • Ongoing intrauterine pregnancy.
  7. Placental abnormality including any of the following:

    • Known placenta accreta;
    • Retained placenta with known risk factors for placenta accreta (e.g., history of prior uterine surgery, including prior c-section and placenta previa);
    • Retained placenta without easy manual removal.
  8. Known uterine rupture.
  9. Unresolved uterine inversion.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Woman who developed PPH after vaginal birth and first line therapies have been attempted and failed

    Group which Alma treatment was applied

    Device: Alma system

Interventions

  • DeviceAlma system

    Subjects diagnosed with postpartum hemorrhage will receive the Alma System. This system comprises a soft silicone cylindrical device placed within the uterus. Gentle suction is applied, prompting the uterus to contract and reduce in size. This contraction compresses the blood vessels, halting the bleeding.

    Also known as: Vacuum induced heamorrhage control, Obstetric-gynecologic specialized manual instrument

06

What researchers measure

Primary outcomes

  1. Rate of Related SAEs

    Rate of device related SAEs up to six weeks following device treatment.

    Time frame: 6 weeks

  2. Rate of Damage to Cervix, Uterus or Vagina

    Rate of any observable damage to cervix, uterus or vagina during or immediately after device procedure

    Time frame: When removing the Alma System at the end of the procedure

  3. Rate of Occurrence of Uterine Inversion or Folding

    Rate of occurrence of uterine inversion or folding during or immediately after device procedure

    Time frame: When removing the Alma System at the end of the procedure

Secondary outcomes

  1. User Feedback on Placement of Alma

    Rate of positive user feedback on device placement trans-vaginally

    Time frame: When removing the Alma System at the end of the procedure

  2. User Feedback on Connection to Vacuum

    Rate of positive user feedback on connection to vacuum and maintenance of desired negative pressure

    Time frame: When removing the Alma System at the end of the procedure

  3. Rate of Uterine Contraction

    Rate of uterine contraction to a level that reduces or stops blood flow

    Time frame: When removing the Alma System at the end of the procedure

  4. Time to Visible Reduction in Blood Flow

    Time from insertion and start of negative pressure to visible reduction in blood flow

    Time frame: When removing the Alma System at the end of the procedure

07

Study locations

1 of 1 sites recruiting
  • UNIVERSITY OF NAIROBI (UoN) COLLEGE OF HEALTH SCIENCES
    Nairobi, Kenya
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jun 2025, 9 months after the start.

Of 112 non-industry interventional studies with no phase under Postpartum Hemorrhage, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 9 months is below that.

Counting every sponsor, half of 119 studies reached it within 16 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2023
First posted
Dec 12, 2023
StartActual
Sep 9, 2024
Primary completionEst.
Jun 2025
CompletionEst.
Jun 2025
Last update
Oct 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06166771
Lead sponsor
ResQ Medical Ltd
Responsible party
Sponsor
First posted
Dec 12, 2023
Start date
Sep 9, 2024
Primary completion
Jun 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
Oct 23, 2024

Study contacts

Omondi Ogutu, Prof. M.D.
Contact
oomogutu@gmail.com
254-722-510215
Alfred Osoti, Prof. M.D.
Contact
alfredos@uonbi.ac.ke
254-733-886664

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion